Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.
Sanofi profit growth beats market view on early start of vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Dengue is spreading and Sanofi is pulling the US market’s only vaccine. What’s next?
As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are raising alarms.
Sanofi Profit, Sales Beat Estimates
The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by earlier-than-anticipated flu and respiratory syncytial virus vaccine purchases.
Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales
Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of Beyfortus, its respiratory syncytial
3h
on MSN
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...
GlobalData on MSN
4d
Sanofi’s $17bn sale of Opella to US investors advances following government deal
A stake by France-owned Bpifrance and promise of local job retention have allayed political backlash over the sale of ...
3d
on MSN
Sanofi in Exclusive Talks With CD&R Over Sale of $17 Billion Opella
PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its ...
4d
Sanofi confirms €16 billion sale of painkiller Doliprane to US investors
French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US ...
4d
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
Sanofi SA (NASDAQ:SNY) and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive negotiations to ...
Opinion
10d
Opinion
US Private Equity’s Sanofi Deal Breaches the French Wall
A health-care buyout has been sealed by an American firm against a rival Gallic offer. That’s despite the asset being a ...
4d
on MSN
Doliprane-maker Sanofi confirms exclusive talks with US firm CD&R
US private equity firm CD&R has agreed to French government demands seeking to protect jobs and investment in France.
4d
Sanofi Pursues Sale Of Painkiller After Political Controversy
Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...
Opinion
2d
Opinion
CD&R Faces Tough Road to 20% Returns With Sanofi
The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than ...
1h
Why Sanofi Stock Flew Higher on Friday
Sanofi attributed its double-digit growth to growth in vaccines, particularly its latest flu jab. Another major revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback